EnteroBiotix raises £19m for Phase 2b IBS-C trial of full-spectrum microbiome therapy
This article covers EnteroBiotix, a healthtech startup, and its closing of a £19m growth funding round to advance its lead candidate EBX-102-02 into a Phase 2b clinical trial for irritable bowel syndrome with constipation (IBS-C). The financing will fund the RISE Phase 2b trial of a full-spectrum microbiome therapeutic, supporting clinical development for patients with IBS-C and providing data relevant to investors and clinicians in the microbiome field.
EnteroBiotix has closed a £19m growth funding round to push its lead candidate, EBX-102-02, into a Phase 2b clinical trial for irritable bowel syndrome with constipation (IBS-C). The cash will underwrite one of the largest interventional studies of a full‑spectrum microbiome therapeutic in IBS, a condition with persistent treatment gaps and substantial patient numbers across Europe and the US.
Why it matters
IBS-C remains a common and debilitating condition with limited options that change the disease course. A large, well‑controlled trial of a microbiome‑based therapy could validate the gut microbiome as a tractable target for symptom reduction or disease modification. The size and scope of the planned study mean its results are likely to influence investor and clinical confidence in microbiome therapeutics in Europe.
Inside the product
EBX-102-02 is EnteroBiotix’s orally delivered, full‑spectrum microbiome therapeutic. The company says the product uses proprietary processing to provide a high‑diversity microbial ecosystem in a stable, orally dosed format. It is not approved for therapeutic use outside clinical trials.
The Phase 2b study, named RISE (Restoring Intestinal Symbiosis for Efficacy in IBS), is a randomised, double‑blind, placebo‑controlled interventional trial that will enrol roughly 300 patients with moderate‑to‑severe IBS-C across UK sites. First patient dosing is expected in Q2 2026, with topline efficacy data anticipated in H2 2027. The programme follows positive Phase 2a TrIuMPH results in 122 patients announced in January 2026.
Who are the investors?
The £19m round was led by life science investor Thairm Bio and the Scottish National Investment Bank, with participation from new and existing backers. EnteroBiotix says the proceeds will fund the RISE Phase 2b trial and support development of a broader gastrointestinal pipeline based on its full‑spectrum approach.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Dr James McIlroy, CEO, EnteroBiotix, said:
Following the positive outcome of our Phase 2a TrIuMPH trial, which demonstrated clear efficacy signals of EBX-102-02 over placebo across key endpoints in patients with irritable bowel syndrome with constipation or diarrhoea, we are now commencing the largest ever full-spectrum microbiome therapeutic trial in IBS. The Phase 2b trial named ‘Restoring Intestinal Symbiosis for Efficacy in IBS’ RISE trial is designed to confirm the earlier signal observed and position EBX-102-02 as a potential first disease-modifying therapy for IBS-C, a highly debilitating condition that is estimated to affect over 10 million people in the USA and Europe , and where unmet need has persisted for decades.
The bigger picture
The financing and trial design underscore two trends in UK healthtech: larger, later‑stage clinical programmes for microbiome therapeutics and continued public and private capital deployment into clinical‑stage biotech. Microbiome products face complex manufacturing, regulatory and placebo‑controlled study challenges, so the outcome of a 300‑patient double‑blind trial will be a key data point for clinicians, regulators and investors.
This funding round and the RISE trial will be watched closely across the UK and Europe as a test case for whether full‑spectrum microbiome approaches can deliver consistent clinical benefits at scale and move beyond small, early‑stage studies into registrational‑style evidence.
They've invested in EnteroBiotix
Get to know these healthtech investors
Click here for a full list of 7,589+ startup investors in the UK